The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Support for biologics manufacturability and Industry 4.0 initiatives
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The ultrasound products manufactured in the new manufacturing facility will be sold under the brand name SonoRad, and are designed for large hospitals, healthcare institutions and individual radiology centres
The total investment is in the region of Rs 200 crore
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Subscribe To Our Newsletter & Stay Updated
